PDS Biotechnology is a clinical stage biopharmaceutical company developing novel cancer immunotherapies and vaccines for infectious diseases.

July 10, 2017 PDS BIOTECHNOLOGY CORP. ANNOUNCES CLINICAL COLLABORATION WITH MERCK TO EVALUATE COMBINATION OF VERSAMUNE® PDS0101 AND KEYTRUDA® (PEMBROLIZUMAB) FOR METASTATIC HEAD AND NECK CANCER

November 8, 2016 DR. ROBERT SHEPARD, MD, CHIEF MEDICAL OFFICER OF PDS BIOTECHNOLOGY TO PRESENT PDS0101 PHASE I/IIA CLINICAL DATA AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) MEETING ON NOVEMBER 11, 2016.

September 19, 2016 BEDU-ADDO TO CHAIR THE THERAPEUTICS/CANCER IMMUNOTHERAPIES SESSION AND PRESENT PHASE I/IIA RESULTS FROM THE PDS0101 PROGRAM AT THE WORLD VACCINE CONGRESS ON OCT 10, 2016

August 24, 2016 PDS ANNOUNCES AGREEMENT WITH FDA ON PHASE 2 CLINICAL PATH FOR PDS0101

April 13, 2016 PDS BIOTECHNOLOGY REPORTS POSITIVE PHASE I/IIA STUDY RESULTS FOR PDS0101 IMMUNOTHERAPY FOR HPV-RELATED CANCERS

February 9, 2016 PDS AND NCI SIGN PHASE 2 CLINICAL CO-DEVELOPMENT AGREEMENT FOR PROSTATE, BREAST AND HPV-CANCERS

January 19, 2016 IMMUNOTHERAPY COMPANY PDS BIOTECHNOLOGY STRENGTHENS SENIOR MANAGEMENT TEAM, ADDS TWO DRUG DEVELOPMENT EXECUTIVES